Trial · NCT00887809
Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes
NCT00887809, Phase 2, Completed, Memorial Sloan Kettering Cancer Center; results first posted 2016-01-25
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes. Trials, record NCT00887809. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00887809
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes
- NCT number
- NCT00887809
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 47 participants, actual
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Conditions
- Sarcoma, Leiomyosarcoma, Malignant Fibrous, Histiocytoma, Angiosarcoma
- Interventions
- gemcitabine, docetaxel, bevacizumab
- First posted
- 2009-04-24
- Last updated
- 2016-01-25
- Results first posted
- 2016-01-25
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall Objective Response | 6 months | Overall Objective Response will be evaluated in this study using the new international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1) |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Overall Objective Response | 6 months | participants | NUMBER |
Source ClinicalTrials.gov
Results by group8
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Objective Response | Gemcitabine, Docetaxel, Bevacizumab | Complete Response (CR) | 0 | participants | |
| Overall Objective Response | Gemcitabine, Docetaxel, Placebo | Complete Response (CR) | 1 | participants | |
| Overall Objective Response | Gemcitabine, Docetaxel, Bevacizumab | Partial Response (PR) | 9 | participants | |
| Overall Objective Response | Gemcitabine, Docetaxel, Placebo | Partial Response (PR) | 1 | participants | |
| Overall Objective Response | Gemcitabine, Docetaxel, Bevacizumab | Stable Disease (SD) | 23 | participants | |
| Overall Objective Response | Gemcitabine, Docetaxel, Placebo | Stable Disease (SD) | 7 | participants | |
| Overall Objective Response | Gemcitabine, Docetaxel, Bevacizumab | Progression of Disease (POD) | 1 | participants | |
| Overall Objective Response | Gemcitabine, Docetaxel, Placebo | Progression of Disease (POD) | 1 | participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Gemcitabine, Docetaxel, Bevacizumab | 37 | |
| Overall Study | STARTED | Gemcitabine, Docetaxel, Placebo | 10 | |
| Overall Study | COMPLETED | Gemcitabine, Docetaxel, Bevacizumab | 33 | |
| Overall Study | COMPLETED | Gemcitabine, Docetaxel, Placebo | 10 | |
| Overall Study | NOT COMPLETED | Gemcitabine, Docetaxel, Bevacizumab | 4 | |
| Overall Study | NOT COMPLETED | Gemcitabine, Docetaxel, Placebo | 0 |
Source ClinicalTrials.gov
Adverse events100
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Albumin, low (hypoalbuminemia) | Metabolism and nutrition disorders | Gemcitabine, Docetaxel, Bevacizumab | 19 | 37 | 19 |
| other | Albumin, low (hypoalbuminemia) | Metabolism and nutrition disorders | Gemcitabine, Docetaxel, Placebo | 6 | 10 | 6 |
| other | Alkaline phosphatase | Metabolism and nutrition disorders | Gemcitabine, Docetaxel, Bevacizumab | 5 | 37 | 5 |
| other | Alkaline phosphatase | Metabolism and nutrition disorders | Gemcitabine, Docetaxel, Placebo | 1 | 10 | 1 |
| other | ALT, SGPT | Blood and lymphatic system disorders | Gemcitabine, Docetaxel, Bevacizumab | 10 | 37 | 10 |
| other | ALT, SGPT | Blood and lymphatic system disorders | Gemcitabine, Docetaxel, Placebo | 3 | 10 | 3 |
| other | AST, SGOT | Blood and lymphatic system disorders | Gemcitabine, Docetaxel, Bevacizumab | 10 | 37 | 10 |
| other | AST, SGOT | Blood and lymphatic system disorders | Gemcitabine, Docetaxel, Placebo | 0 | 10 | 0 |
| other | Bilirubin (hyperbilirubinemia) | Metabolism and nutrition disorders | Gemcitabine, Docetaxel, Bevacizumab | 3 | 37 | 3 |
| other | Bilirubin (hyperbilirubinemia) | Metabolism and nutrition disorders | Gemcitabine, Docetaxel, Placebo | 1 | 10 | 1 |
1 to 10 of 100Source ClinicalTrials.gov
See all 100 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Gemcitabine, Docetaxel, Bevacizumab | ||
| Total, all-cause mortality | Gemcitabine, Docetaxel, Placebo | ||
| Total, other adverse events | Gemcitabine, Docetaxel, Bevacizumab | 33 | 37 |
| Total, other adverse events | Gemcitabine, Docetaxel, Placebo | 10 | 10 |
| Total, serious adverse events | Gemcitabine, Docetaxel, Bevacizumab | 12 | 37 |
| Total, serious adverse events | Gemcitabine, Docetaxel, Placebo | 6 | 10 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Gemcitabine, Docetaxel, Bevacizumab vs Gemcitabine, Docetaxel, Placebo: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00887809
GET https://conductscience.org/api/trials/v1/NCT00887809/events?page=2